Related Experiment Videos
Trastuzumab-based combination therapy for breast cancer
Filippo Montemurro1, Giorgio Valabrega, Massimo Aglietta
1Division of Oncology, Institute for Cancer Research and Treatment, Strada Provinciale 142, 10060 Candiolo, Torino, Italy. fmontemurro@ircc.mauriziano.it
Expert Opinion on Pharmacotherapy
|December 19, 2003
Summary
Trastuzumab, an antibody targeting HER-2, effectively treats HER-2-overexpressing metastatic breast cancer. Combinations with chemotherapy improve outcomes, with ongoing research exploring various chemotherapy agents to optimize treatment and minimize side effects.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Trastuzumab is a targeted therapy for HER-2-positive breast cancer.
- Preclinical data suggest synergistic effects between trastuzumab and chemotherapy agents.
- Clinical trials have demonstrated improved outcomes with trastuzumab plus chemotherapy.
Purpose of the Study:
- To review data on trastuzumab-based combination therapies for breast cancer.
- To summarize efficacy and safety profiles of various trastuzumab combinations.
- To inform clinical practice regarding HER-2-positive breast cancer treatment.
Main Methods:
- Review of preclinical studies and clinical trials.
- Analysis of data from randomized Phase III trials.
- Summary of combination therapies including docetaxel, vinorelbine, platinum salts, gemcitabine, and capecitabine.
Main Results:
- Trastuzumab monotherapy and combination therapy show activity in HER-2-overexpressing metastatic breast cancer.
- Trastuzumab plus chemotherapy improves response rates and survival.
- Cardiotoxicity concerns with anthracyclines led to investigation of alternative combinations.
Conclusions:
- Trastuzumab-based combinations are a cornerstone in treating HER-2-positive metastatic breast cancer.
- Various chemotherapy agents can be effectively combined with trastuzumab.
- Further research is warranted to optimize treatment strategies and manage potential toxicities.